- Home
- XNCR vs EVMN Comparison
XNCR vs EVMN Comparison
Compare XNCR & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XNCR | EVMN |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 881.9M | 892.4M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | XNCR | EVMN |
|---|---|---|
| Price | $11.29 | $26.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $22.89 | ★ $44.17 |
| AVG Volume (30 Days) | 560.6K | ★ 945.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,576,000.00 | N/A |
| Revenue This Year | N/A | $89.43 |
| Revenue Next Year | $6.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.65 | N/A |
| 52 Week Low | $6.92 | $13.89 |
| 52 Week High | $18.69 | $33.20 |
Technical Indicators
Market Signals| Indicator | XNCR | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 54.98 |
| Support Level | $11.02 | $15.25 |
| Resistance Level | $12.58 | $33.20 |
| Average True Range (ATR) | 0.89 | 2.65 |
| MACD | 0.03 | -0.60 |
| Stochastic Oscillator | 16.33 | 42.21 |
Price Performance
Historical ComparisonAbout XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.